Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Systematic Reviews
Published in: Systematic Reviews 1/2014

Open Access 01-12-2014 | Protocol

The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol

Authors: Brittany Burns Dennis, Leen Naji, Monica Bawor, Ashley Bonner, Michael Varenbut, Jeff Daiter, Carolyn Plater, Guillaume Pare, David C Marsh, Andrew Worster, Dipika Desai, Zainab Samaan, Lehana Thabane

Published in: Systematic Reviews | Issue 1/2014

Login to get access

Abstract

Background

Opioids are psychoactive analgesic drugs prescribed for pain relief and palliative care. Due to their addictive potential, effort and vigilance in controlling prescriptions is needed to avoid misuse and dependence. Despite the effort, the prevalence of opioid use disorder continues to rise. Opioid substitution therapies are commonly used to treat opioid dependence; however, there is minimal consensus as to which therapy is most effective. Available treatments include methadone, heroin, buprenorphine, as well as naltrexone. This systematic review aims to assess and compare the effect of all available opioid substitution therapies on the treatment of opioid dependence.

Methods/Design

The authors will search Medline, EMBASE, PubMed, PsycINFO, Web of Science, Cochrane Library, Cochrane Clinical Trials Registry, World Health Organization International Clinical Trials Registry Platform Search Portal, and the National Institutes for Health Clinical Trials Registry. The title, abstract, and full-text screening will be completed in duplicate. When appropriate, multiple treatment comparison Bayesian meta-analytic methods will be performed to deduce summary statistics estimating the effectiveness of all opioid substitution therapies in terms of retention and response to treatment (as measured through continued opioid abuse).

Discussion

Using evidence gained from this systematic review, we anticipate disseminating an objective review of the current available literature on the effectiveness of all opioid substitution therapies for the treatment of opioid use disorder. The results of this systematic review are imperative to the further enhancement of clinical practice in addiction medicine.

Systematic review registration

PROSPERO CRD42013006507.
Appendix
Available only for authorised users
Literature
1.
Franklin GM, Rahman EA, Turner JA, Daniell WE, Fulton-Kehoe D: Opioid use for chronic low back pain: A prospective, population-based study among injured workers in Washington state, 2002-2005. Clin J Pain. 2009, 25 (9): 743-751. 10.1097/AJP.0b013e3181b01710.CrossRefPubMed
2.
3.
Association AP: Diagnostic and statistical manual of mental disorders. 2013, Arlington, VA: American Psychiatric Publishing, 5
4.
Gugelmann HM, Perrone J: Can prescription drug monitoring programs help limit opioid abuse?. JAMA. 2011, 306 (20): 2258-2259.CrossRefPubMed
5.
Sproule B, Brands B, Li S, Catz-Biro L: Changing patterns in opioid addiction: characterizing users of oxycodone and other opioids. Can Fam Physician. 2009, 55 (1): 68-69. 69.e61-65PubMedPubMedCentral
6.
Nicholls L, Bragaw L, Ruetsch C: Opioid dependence treatment and guidelines. J Manag Care Pharm. 2010, 16 (1 Suppl B): S14-S21.PubMed
7.
Dhalla IA, Mamdani MM, Sivilotti ML, Kopp A, Qureshi O, Juurlink DN: Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ. 2009, 181 (12): 891-896. 10.1503/cmaj.090784.CrossRefPubMedPubMedCentral
8.
9.
CfDCa P: Policy impact: prescription painkiller overdoses. 2013, USA, Atlanta
10.
Chong E, Poh KK, Shen L, Yeh IB, Chai P: Infective endocarditis secondary to intravenous Subutex abuse. Singap Med J. 2009, 50 (1): 34-42.
11.
Ho RC, Ho EC, Tan CH, Mak A: Pulmonary hypertension in first episode infective endocarditis among intravenous buprenorphine users: case report. Am J Drug Alcohol Abuse. 2009, 35 (3): 199-202. 10.1080/00952990902939719.CrossRefPubMed
12.
Zhang L, Zhang D, Chen W, Zou X, Ling L: High prevalence of HIV, HCV and tuberculosis and associated risk behaviours among new entrants of methadone maintenance treatment clinics in Guangdong Province. China PLoS One. 2013, 8 (10): e76931-10.1371/journal.pone.0076931.CrossRefPubMed
13.
Methadone maintenance treatment program standards and clinical guidelines. 2011, Toronto, Canada: The College of Physicians and Surgeons of Ontario, 4
14.
15.
Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ: Selected major risk factors and global and regional burden of disease. Lancet. 2002, 360 (9343): 1347-1360. 10.1016/S0140-6736(02)11403-6.CrossRefPubMed
16.
Metzger DS, Woody GE, McLellan AT, O'Brien CP, Druley P, Navaline H, DePhilippis D, Stolley P, Abrutyn E: Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr. 1993, 6 (9): 1049-1056.PubMed
17.
Zou S, Tepper M, Giulivi A: Current status of hepatitis C in Canada. Can J Public Health. 2000, 91 (Suppl 1): S10-S15. s10–16PubMed
18.
Wall R, Rehm J, Fischer B, Brands B, Gliksman L, Stewart J, Medved W, Blake J: Social costs of untreated opioid dependence. J Urban Health. 2000, 77 (4): 688-722. 10.1007/BF02344032.CrossRefPubMedPubMedCentral
19.
Oppenheimer E, Tobutt C, Taylor C, Andrew T: Death and survival in a cohort of heroin addicts from London clinics: a 22-year follow-up study. Addiction. 1994, 89 (10): 1299-1308. 10.1111/j.1360-0443.1994.tb03309.x.CrossRefPubMed
20.
Seal KH, Kral AH, Gee L, Moore LD, Bluthenthal RN, Lorvick J, Edlin BR: Predictors and prevention of nonfatal overdose among street-recruited injection heroin users in the San Francisco Bay Area, 1998-1999. Am J Public Health. 2001, 91 (11): 1842-1846. 10.2105/AJPH.91.11.1842.CrossRefPubMedPubMedCentral
21.
22.
Li Y, Kantelip JP, Gerritsen-van Schieveen P, Davani S: Interindividual variability of methadone response: impact of genetic polymorphism. Mol Diagn Ther. 2008, 12 (2): 109-124. 10.1007/BF03256276.CrossRefPubMed
23.
Crettol S, Monnat M, Eap CB: Could pharmacogenetic data explain part of the interindividual sensitivity to methadone-induced respiratory depression?. Crit Care. 2007, 11 (1): 119-10.1186/cc5699.CrossRefPubMedPubMedCentral
24.
Eap CB, Buclin T, Baumann P: Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002, 41 (14): 1153-1193. 10.2165/00003088-200241140-00003.CrossRefPubMed
25.
Eap CB, Bertschy G, Baumann P, Finkbeiner T, Gastpar M, Scherbaum N: High interindividual variability of methadone enantiomer blood levels to dose ratios. Arch Gen Psychiatry. 1998, 55 (1): 89-90. 10.1001/archpsyc.55.1.89.CrossRefPubMed
26.
Yang F, Tong X, McCarver DG, Hines RN, Beard DA: Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model. J Pharmacokinet Pharmacodyn. 2006, 33 (4): 485-518. 10.1007/s10928-006-9018-0.CrossRefPubMed
27.
Fischer B, Chin AT, Kuo I, Kirst M, Vlahov D: Canadian illicit opiate users' views on methadone and other opiate prescription treatment: an exploratory qualitative study. Subst Use Misuse. 2002, 37 (4): 495-522. 10.1081/JA-120002807.CrossRefPubMed
28.
Simon-Sanchez J, Singleton AB: Sequencing analysis of OMI/HTRA2 shows previously reported pathogenic mutations in neurologically normal controls. Hum Mol Genet. 2008, 17 (13): 1988-1993. 10.1093/hmg/ddn096.CrossRefPubMedPubMedCentral
29.
Mendelson J, Jones RT, Welm S, Baggott M, Fernandez I, Melby AK, Nath RP: Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology (Berl). 1999, 141 (1): 37-46. 10.1007/s002130050804.CrossRef
30.
Bell J, Byron G, Gibson A, Morris A: A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence. Drug Alcohol Rev. 2004, 23 (3): 311-317. 10.1080/09595230412331289473.CrossRefPubMed
31.
Orman JS, Keating GM: Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence. Drugs. 2009, 69 (5): 577-607. 10.2165/00003495-200969050-00006.CrossRefPubMed
32.
Whelan PJ, Remski K: Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds. J Neurosci Rural Pract. 2012, 3 (1): 45-50. 10.4103/0976-3147.91934.CrossRefPubMedPubMedCentral
33.
Curcio F, Franco T, Topa M, Baldassarre C: Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey. Eur Rev Med Pharmacol Sci. 2011, 15 (8): 871-874.PubMed
34.
Sullivan MA, Bisaga A, Mariani JJ, Glass A, Levin FR, Comer SD, Nunes EV: Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade?. Drug Alcohol Depend. 2013, 133 (1): 80-85. 10.1016/j.drugalcdep.2013.05.030.CrossRefPubMedPubMedCentral
35.
36.
Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O'Brien CP: Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006, 63 (2): 210-218. 10.1001/archpsyc.63.2.210.CrossRefPubMedPubMedCentral
37.
Krupitsky E, Zvartau E, Woody G: Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available. Curr Psychiatry Rep. 2010, 12 (5): 448-453. 10.1007/s11920-010-0135-5.CrossRefPubMedPubMedCentral
38.
Gibson AE, Degenhardt LJ: Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records. Drug Alcohol Rev. 2007, 26 (4): 405-410. 10.1080/09595230701373834.CrossRefPubMed
39.
Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, Schechter MT: Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009, 361 (8): 777-786. 10.1056/NEJMoa0810635.CrossRefPubMed
40.
Nosyk B, Guh DP, Bansback NJ, Oviedo-Joekes E, Brissette S, Marsh DC, Meikleham E, Schechter MT, Anis AH: Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment. CMAJ. 2012, 184 (6): E317-E328. 10.1503/cmaj.110669.CrossRefPubMedPubMedCentral
41.
Cohen J: A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960, 20 (1): 37-46. 10.1177/001316446002000104.CrossRef
42.
Stroup DFBJ, Morton SC, Olkin I, Williamson GD, Rennie D: Meta-analysis of Observational Studies in Epidemiology. JAMA. 2000, 283 (15): 2008-2012. 10.1001/jama.283.15.2008.CrossRefPubMed
43.
Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010, 8 (5): 336-341. 10.1016/j.ijsu.2010.02.007.CrossRefPubMed
44.
45.
46.
Hser YI, Anglin D, Powers K: A 24-year follow-up of California narcotics addicts. Arch Gen Psychiatry. 1993, 50 (7): 577-584. 10.1001/archpsyc.1993.01820190079008.CrossRefPubMed
47.
Maas J, Barton G, Maskrey V, Pinto H, Holland R: Economic evaluation: A comparison of methadone versus buprenorphine for opiate substitution treatment. Drug Alcohol Depend. 2013, 133 (2): 494-501. 10.1016/j.drugalcdep.2013.07.018.CrossRefPubMed
48.
Mattick RP, Ali R, White JM, O'Brien S, Wolk S, Danz C: Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction (Abingdon, England). 2003, 98 (4): 441-452. 10.1046/j.1360-0443.2003.00335.x.CrossRef
49.
Samaan Z, Bawor M, Dennis B, Plater C, Worster A, Varenbut M, Daiter J, Marsh DC, Desai D, Thabane L, Pare G: Genetic influence in methadone dose and response to treatment in patients undergoing Methadone Maintenance Treatment (MMT) for opioid addiction: A pilot study. J Neuropsychiatr Dis Treat. 2014
50.
Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D, Buprenorphine/Naloxone Collaborative Study Group: Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003, 349 (10): 949-958. 10.1056/NEJMoa022164.CrossRefPubMed
51.
Ling W, Amass L, Shoptaw S, Annon JJ, Hillhouse M, Babcock D, Brigham G, Harrer J, Reid M, Muir J, Buchan B, Orr D, Woody G, Kreici J, Ziedonis D, Buprenorphine Study Protocol Group: A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction. 2005, 100 (8): 1090-1100. 10.1111/j.1360-0443.2005.01154.x.CrossRefPubMedPubMedCentral
52.
Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, Jacobs P, Teruya C, McLaughlin P, Wiest K, Cohen A, Ling W: Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction. 2014, 109 (1): 79-87. 10.1111/add.12333.CrossRefPubMed
53.
Deck D, Carlson MJ: Retention in publicly funded methadone maintenance treatment in two Western States. J Behav Health Serv Res. 2005, 32 (1): 43-60. 10.1007/BF02287327.CrossRefPubMed
54.
Apelt SM, Scherbaum N, Golz J, Backmund M, Soyka M: Safety, effectiveness and tolerance of buprenorphine-naloxone in the treatment of opioid dependence: results from a nationwide non-interventional study in routine care. Pharmacopsychiatry. 2013, 46 (3): 94-107.CrossRefPubMed
55.
Concato J, Shah N, Horwitz RI: Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000, 342 (25): 1887-1892. 10.1056/NEJM200006223422507.CrossRefPubMedPubMedCentral
56.
Benson K, Hartz AJ: A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000, 342 (25): 1878-1886. 10.1056/NEJM200006223422506.CrossRefPubMed
57.
The Cochrane Collaboration. The Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Edited by: Higgins JPT, Green S. 2011
58.
Navarese EP, Kozinski M, Pafundi T, Andreotti F, Buffon A, Servi SD, Kubica J: Practical and updated guidelines on performing meta-analyses of non-randomized studies in interventional cardiology. Cardiol J. 2011, 18 (1): 3-7.PubMed
59.
Knapp G, Hartung J: Improved tests for a random effects meta-regression with a single covariate. Stat Med. 2003, 22 (17): 2693-2710. 10.1002/sim.1482.CrossRefPubMed
60.
R: RDCT: R: A language for statistical computing. Vienna R Foundation for Statistical Computing.
61.
Cornell JE, Mulrow CD, Localio R, Stack CB, Meibohm AR, Guallar E, Goodman SN: Random-effects meta-analysis of inconsistent effects: a time for change. Ann Intern Med. 2014, 160 (4): 267-270.CrossRefPubMed
62.
DerSimonian R, Kacker R: Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2007, 28 (2): 105-114. 10.1016/j.cct.2006.04.004.CrossRefPubMed
63.
Mills EJ, Ioannidis JP, Thorlund K, Schunemann HJ, Puhan MA, Guyatt GH: How to use an article reporting a multiple treatment comparison meta-analysis. JAMA. 2012, 308 (12): 1246-1253. 10.1001/2012.jama.11228.CrossRefPubMed
64.
Silva PS, Reis ME, Aguiar VE, Fonseca MC: Unplanned extubation in the neonatal ICU: a systematic review, critical appraisal, and evidence-based recommendations. Respir Care. 2013, 58 (7): 1237-1245. 10.4187/respcare.02164.CrossRefPubMed
65.
Lumley T: Network meta-analysis for indirect treatment comparisons. Stat Med. 2002, 21 (16): 2313-2324. 10.1002/sim.1201.CrossRefPubMed
66.
Veroniki AA, Vasiliadis HS, Higgins JP, Salanti G: Evaluation of inconsistency in networks of interventions. Int J Epidemiol. 2013, 42 (1): 332-345. 10.1093/ije/dys222.CrossRefPubMed
67.
Higgins J: Identifying and addressing inconsistency in network meta-analysis. Cochrane Comparing Multiple Interventions Methods Group Oxford Training Event: 2013. 2013, Cochrane Collaboration
68.
Dias S, Welton NJ, Caldwell DM, Ades AE: Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010, 29 (7–8): 932-944.CrossRefPubMed
69.
Salanti G, Ades AE, Ioannidis JP: Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011, 64 (2): 163-171. 10.1016/j.jclinepi.2010.03.016.CrossRefPubMed
70.
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, Schünemann HJ: GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011, 64 (4): 383-394. 10.1016/j.jclinepi.2010.04.026.CrossRefPubMed
71.
Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, Alonso-Coello P, Falck-Ytter Y, Jaeschke R, Vist G, Akl EA, Post PN, Norris S, Meerpohl J, Shukla VK, Nasser M, Schünemann HJ, GRADE Working Group: GRADE guidelines: 8. Rating the quality of evidence—indirectness. J Clin Epidemiol. 2011, 64 (12): 1303-1310. 10.1016/j.jclinepi.2011.04.014.CrossRefPubMed
Metadata
Title
The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol
Authors
Brittany Burns Dennis
Leen Naji
Monica Bawor
Ashley Bonner
Michael Varenbut
Jeff Daiter
Carolyn Plater
Guillaume Pare
David C Marsh
Andrew Worster
Dipika Desai
Zainab Samaan
Lehana Thabane
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Systematic Reviews / Issue 1/2014
Electronic ISSN: 2046-4053
DOI
https://doi.org/10.1186/2046-4053-3-105

Other articles of this Issue 1/2014

Systematic Reviews 1/2014 Go to the issue

Protocol

Financial incentive policies at workplace cafeterias for preventing obesity—a systematic review and meta-analysis (Protocol)

Methodology

SAMURAI: Sensitivity analysis of a meta-analysis with unpublished but registered analytical investigations (software)

Protocol

The association between proximity to animal-feeding operations and community health: a protocol for updating a systematic review

Protocol

Seeing the forests and the trees—innovative approaches to exploring heterogeneity in systematic reviews of complex interventions to enhance health system decision-making: a protocol

Protocol

Effects of lifestyle modification after breast cancer treatment: a systematic review protocol

Protocol

Prosthetic heart valves in pregnancy: a systematic review and meta-analysis protocol